Abstract. The MUC1 oncoprotein is aberrantly overexpressed in human carcinomas and hematologic malignancies. MicroRNAs (miRNAs) have been implicated in the suppression and induction of oncogenesis. The present studies demonstrate that the MUC1 mRNA 3' untranslated region (3'UTR) contains a highly conserved motif for binding of a novel miRNA, miR-1226, that has no known targets. The results show that miR-1226 is expressed in human breast cancer cell lines and non-malignant mammary epithelial cells. We also show that miR-1226 interacts with the MUC1 mRNA 3'UTR and that miR-1226 downregulates endogenous MUC1 protein levels. Consistent with miR-1226-induced downregulation of MUC1 expression, the results demonstrate that miR-1226 induces i) an increase in reactive oxygen species, ii) loss of the mitochondrial transmembrane potential, and iii) a decrease in cell survival. These findings indicate that expression of the MUC1 oncoprotein is downregulated by miR-1226 and that miR-1226 thereby functions as a tumor suppressor by promoting the induction of cell death.
Introduction
The mucin 1 (MUC1) oncoprotein is aberrantly expressed in most human carcinomas and certain hematologic malignancies (1) . The upregulation of MUC1 expression has been attributed to activation of the MUC1 gene (1) , and amplification and rearrangements of the MUC1 locus (2, 3) . Following transcription, MUC1 is translated as a single polypeptide, undergoes autocleavage into two subunits, which in turn form a stable heterodimer (1) . The MUC1 N-terminal subunit (MUC1-N) contains a glycosylated tandem repeat structure that is characteristic of mucins (1) . By contrast, the MUC1 C-terminal subunit functions as a transmembrane receptor that also tethers MUC1-N to the cell surface and interacts with members of the receptor tyrosine kinase family (1, 4) . Significantly, the MUC1-C 72 amino acid cytoplasmic domain (MUC1-CD) is sufficient to induce transformation (5, 6) . In this regard, MUC1-CD interacts with diverse effectors, such as ß-catenin (6,7), p53 (8) , IκB kinase (9) and NF-κB p65/RelA (10) that contribute to the induction of transformation. The overexpression of MUC1 in malignant cells is associated with accumulation of MUC1-C in the cytoplasm and targeting of MUC1-C to the nucleus (11) , where it participates in the regulation of target genes activated by diverse transcription factors (8, 10, 12, 13) . MUC1-C is also targeted to the mitochondrial outer membrane, where it protects against stress-induced loss of the mitochondrial transmembrane potential (14, 15) . In concert with these observations, overexpression of MUC1-C blocks the induction of apoptosis and necrosis in the response of human cancer cells to genotoxic stress (14) , reactive oxygen species (16, 17) , hypoxia (18) , glucose deprivation (19) and activation of death receptors (20) . These findings have provided substantial evidence that dysregulation of MUC1 expression is of importance to the malignant phenotype.
MicroRNAs (miRNAs) are a class of small (~22 nucleotides) non-coding RNAs that posttranscriptionally regulate gene expression (21) . miRNAs interact in a sequencespecific manner with the 3' untranslated region (3'UTR) or, in some settings, with amino acid coding regions of their mRNA targets (22) . Expression of the target is thereby directed by miRNA-induced mRNA degradation or inhibition of translation (23) . The identification of aberrant patterns of miRNA expression in human cancers has indicated that miRNAs can function in oncogenesis and as tumor suppressors (24) . Mechanisms that have been attributed to aberrant miRNA expression in malignant cells include chromosomal alterations, epigenetic modifications, mutations, polymorphisms and defective miRNA biogenesis (24) . Dysregulation of miRNA expression has been found in diverse carcinomas and hematologic malignancies, and has been linked to alterations in cell growth, survival and metastasis (24, 25) . For example, miR-15 and miR-16 were first identified as regulators of Bcl-2 and thereby the apoptotic response (26) . Other miRNAs have been implicated in regulating TRAIL-induced activation of the extrinsic apoptotic pathway (25) . Moreover, the miR-34 family is induced by p53 and regulates genes involved in the p53-dependent growth arrest and apoptotic responses (27, 28) . Other work has demonstrated that miR125b is a negative regulator of p53 expression and the induction of apoptosis (29) . These findings have collectively provided convincing support for the importance of miRNAs in regulating the apoptotic response of cancer cells.
The present work demonstrates that miR-1226, a miRNA with no known target transcripts, is a novel negative regulator of MUC1 expression. The results also demonstrate that miR-1226-induced downregulation of MUC1 is associated with death of MUC1-positive breast cancer cells.
Materials and methods
Cell culture. Human MCF-7 and MDA-MB-231 breast cancer and 293 embryonic kidney cells (ATCC) were cultured in Dulbecco's modified Eagle's medium supplemented with 10% heat-inactivated fetal bovine serum (FBS) containing 100 U/ml penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine. RT-PCR. Total RNA was isolated from cells using the mirVana miRNA Isolation Kit (Ambion). cDNAs were synthesized using the Ncode miRNA first-strand cDNA synthesis kit (Invitrogen). Expression of miR-1226 and MUC1 was analyzed with Taq DNA polymerase (Qiagen).
Immunoblot analysis.
Lysates from subconfluent cells were prepared as described (14) and subjected to immunoblotting with anti-MUC1-C (Ab5; NeoMarkers) and anti-ß-actin (AC-15; Sigma-Aldrich). Immune complexes were detected with horseradish peroxidase-conjugated secondary antibodies and enhanced chemiluminescence (Amersham Biosciences). Luciferase reporter assays. The human MUC1 3'UTR was ligated into the pMIR-REPORT expression vector (Ambion). Mutation and deletion of the MUC1 3'UTR at the miR-1226 binding site was performed using the QuickChange XL sitedirected mutagenesis kit (Stratagene). Cells were cotransfected with the pMIR-MUC1 3'UTR vectors, pRL-TK (Promega) and the miR-1226 mimic or negative control mimic in the presence of Lipofectamine 2000. At 48 h after transfection, the cells were analyzed for firefly and Renilla luciferase activities using the Dual Luciferase Assay Kit (Promega).
Measurement of ROS levels. Cells were incubated in PBS containing 10 μM DCFH-AM for 30 min at 37˚C in the dark to assess H 2 O 2 -mediated oxidation of DCFH-AM to the fluorescent DCF. Fluorescence of DCF was measured by flow cytometry.
Measurement of the mitochondrial transmembrane potential.
Cells were incubated in PBS containing 500 ng/ml rhodamine 123 (Molecular Probes) for 20 min at 37˚C in the dark. Samples were washed in PBS and analyzed by flow cytometry.
Assessment of cell death. Cells were incubated in binding buffer containing FITC-conjugated Annexin V and propidium iodide (PI) (BD Pharmingen) for 15 min at room temperature in the dark and then analyzed by flow cytometry. For clonogenic survival assays, cells were seeded in six-well plates. After two weeks, colonies were stained with crystal violet and counted as positive when containing over 50 cells.
Results

Human MUC1 3'UTR contains a putative element for miR-1226 binding.
To assess the possible regulation of MUC1 expression by miRNAs, we searched the human MUC1 321 base-pair (bp) 3'UTR for potential miRNA binding sites using TargetScanHuman 5.1 (30) (31) (32) . A putative response element for miR-1226 was identified at 76-97 bp downstream of the stop-codon (Fig. 1A) . Searches for miR-1226 targets by TargetScan and miRanda (33) confirmed that the MUC1 3'UTR contains a potential miR-1226 binding site. In this regard, the MUC1 3'UTR sequence GGGCUGGUGA has perfect complimentarity with bases 1 through 10 counting from the 5' end of miR-1226 (Fig. 1A) . MUC1 homologs are restricted to mammalian species (34) . Highly conserved putative miR-1226 response elements were found in the human MUC1 3'UTR and that of other vertebrates, indicating that miR-1226 may be of importance as a regulator of MUC1 expression (Fig. 1B) . The precursor sequence for miR-1226 is localized on chromosome 3 (35) . Otherwise, there are no published reports on miR-1226 expression or function. Analysis of human MDA-MB-231, BT-549 and MCF-7 breast cancer cell lines demonstrated expression of miR-1226 (Fig. 1C) . By contrast, ZR-75-1 breast cancer cells had somewhat lower levels of miR-1226 expression (Fig. 1C) . miR-1226 was also detectable in non-malignant human MCF-10A mammary epithelial cells (Fig. 1C) . MUC1 mRNA levels were lower in MDA-MB-231 cells (Fig. 1D , upper panels). For comparison, MUC1 protein levels were elevated in ZR-75-1 cells as compared to that in MCF-7 and BT-549 cells (Fig. 1D, lower panels) . Moreover, MUC1 expression was relatively lower in MDA-MB-231 and MCF-10A cells, although detectable upon longer radiographic exposures (Fig. 1D , lower panels; data not shown).
MUC1 expression is suppressed by miR-1226.
To assess binding of miR-1226 to the putative target sequence, the region containing the human MUC1 3'UTR was cloned into the pMIR-luciferase reporter (pMIR-MUC1 3'UTR). As controls, the MUC1 3'UTR was mutated (4-base mismatch; pMIR-MUC1 mut3'UTR) or deleted (pMIR-MUC1 del3'UTR) in the GCUGGUG sequence ( Fig. 2A, upper) . Transfection of 293 cells with pMIR-MUC1 3'UTR and a miR-1226 mimic was associated with downregulation of luciferase activity ( Fig. 2A, lower) . Compared to wild-type pMIR-MUC1 3'UTR, expression of the mutated pMIR-MUC1 mut3'UTR vector was unaffected by the miR-1226 mimic ( Fig. 2A, lower) . Deletion of GCUGGUG in pMIR-MUC1 del3'UTR also abrogated downregulation of expression by the miR-1226 mimic ( Fig. 2A, lower) , indicating that the predicted response element is essential for direct binding of miR-1226. To determine whether miR-1226 regulates endogenous MUC1 expression by decreasing mRNA stability, we studied MCF-7 cells transfected to overexpress the control or miR-1226 mimics. RT-PCR analysis demonstrated that miR-1226 has little if any effect on MUC1 mRNA levels (Fig. 2B) . Similar findings were obtained with MCF-10A cells expressing control and miR-1226 mimics (Fig. 2C) . By contrast, expression of MUC1-C protein was suppressed by miR-1226 in both MCF-7 and MCF-10A cells (Fig. 2D) . These findings indicate that miR-1226 interacts with the MUC1 3'UTR and suppresses MUC1 translation.
miR-1226 overexpression increases ROS levels and induces loss of mitochondrial transmembrane potential.
Previous work has demonstrated that MUC1-C suppresses intracellular oxidant levels (16) (17) (18) (19) . Consistent with these findings, expression of the miR-1226, and not the control, mimic in MCF-7 cells was associated with an increase in ROS levels (Fig. 3A, left) . Expression of the miR-1226 mimic similarly disrupted redox balance in MCF-10A cells (Fig. 3A, right) , indicating that this response occurs in both malignant and non-malignant mammary epithelial cells. Other studies have shown that MUC1 protects against stress-induced loss of the mitochondrial transmembrane potential (Δ"m) (14, 15) . Significantly, downregulation of MUC1 and disruption of redox balance by miR-1226 was also associated with loss of Δ"m in both MCF-7 and MCF-10A cells (Fig. 3B and C) .
Overexpression of miR-1226 decreases cell survival.
To determine whether miR-1226-induced disruption of redox balance and loss of Δ"m affects survival, cells expressing the control and miR-1226 mimics were first monitored for effects on growth. As compared to the controls, growth of MCF-7 ( Fig. 4A ) and MCF-10A (Fig. 4B ) cells was decreased by expression of the miR-1226 mimic. In support of MUC1 as a target, silencing MUC1 expression with a MUC1 siRNA pool was associated with slowing of MCF-7 cell growth (Fig. 4C) . Similar effects were observed in MCF-10A cells (Fig. 4D) .
Assessment of cell survival by colony formation assays further demonstrated a substantial decrease in MCF-7 cells expressing miR-1226 as compared to the control mimic (Fig. 5A, left) . Analysis of repetitive experiments confirmed that miR-1226 decreases MCF-7 colony formation by nearly 75% (Fig. 5A, right) . Similar effects were observed with MCF-10A cells expressing miR-1226 (Fig. 5B . left) with a decrease of over 50% in colony formation (Fig. 5B, right) . In addition, miR-1226 had little if any effect on growth and survival of MUC1-negative 293 cells (Fig. 5C ).
miR-1226 induces late apoptosis/necrosis. MUC1 attenuates the apoptotic and necrotic death responses to oxidative stress (16) (17) (18) (19) . To determine the basis for miR-1226-induced death, cells were visualized by bright field microscopy and after staining with DAPI. Expression of the miR-1226 mimic was associated with rounding-up of the MCF-7 cells and nuclear condensation, consistent with an apoptotic response (Fig. 6A) . Similar results were obtained with MCF-10A cells expressing the miR-1226 mimic (Fig. 6B) . To extend and quantitate these observations, the cells were stained with PI/Annexin V and analyzed by flow cytometry. For MCF-7 cells expressing the miR-1226 mimic, 44% were Annexin V-positive as compared to 14% for those expressing the control (Fig. 6C,  upper panels) . These results were confirmed in repetitive experiments (Fig. 6C, lower panel) . In addition, about half of the Annexin V-positive cells had increased PI uptake, consistent with the induction of late apoptosis/necrosis. Expression of the miR-1226 mimic in MCF-10A cells was also associated with a significant increase in Annexin Vpositive cells, many of which exhibited PI uptake (Fig. 6D) , indicating the induction of predominantly a late apoptotic/ necrotic response. Constitutive activation of the STAT3 and NF-κB pathways in human cancers contributes, at least in part, to aberrant induction of the MUC1 promoter (10, 36) . In addition, recent studies have demonstrated that MUC1 expression is regulated by post-transcriptional mechanisms involving interactions of the 321 bp MUC1 3'UTR with miR-145 and miR-125b (37, 38) . In the present work, we found that the MUC1 3'UTR contains a GGGCUGGUGA sequence that has perfect complimentarity with the 5' region of miR-1226. As determined by site-directed mutagenesis, we also found that miR-1226 interacts with this motif. Little is known about miR-1226 other than the pre-miR-1226 locus resides on chromosome 3 (35) . The results shown here demonstrate that miR-1226 is expressed in human breast cancer cells and nonmalignant mammary epithelial cells. Studies using human prostate and other types of cancer cells also identified miR-1226 expression (data not shown), indicating that this miRNA may be widely detectable in malignant cells that overexpress MUC1. In addition, analysis of human 3'UTRs identified putative miR-1226 binding sequences with perfect 7-bp matches in 29 additional genes (Table I) , one of which, BCL2L1 encoding Bcl-xL is known to be linked to MUC1 signaling pathways (10) . Whereas further experimentation is underway to determine if miR-1226 regulates expression of these genes, in the present focus on MUC1, we found that miR-1226 confers a decrease in MUC1 protein levels. These findings and those of MUC1 promoter activation (1) indicate that overexpression of MUC1 in breast cancer cells is a function of multiple events that are dysregulated at both the transcriptional and post-transcriptional levels.
miR-1226 induces cell death by promoting apoptosis/ necrosis. miR-15 and miR-16 downregulate expression of the anti-apoptotic Bcl-2 protein and thereby contribute to activation of the intrinsic apoptotic pathway (39) . Other miRNAs have been linked to the downregulation of antiapoptotic factors, for example, miR-29 and the Mcl-1 protein (25) . The MUC1-C subunit is targeted to the mitochondrial outer membrane, where it attenuates loss of Δaem in the response to DNA damage, ROS and other forms of stress that activate the intrinsic apoptotic pathway (1, 14, 15) . MUC1-C has also been implicated in suppressing redox imbalance (16) , for example as a result of mitochondrial dysfunction and increases in ROS production (40, 41) . In concert with these findings, miR-1226-induced downregulation of MUC1 expression was associated with increases in ROS and loss of Δaem. Moreover, miR-1226 expression in MCF-7 cells resulted in induction of a late apoptotic/necrotic response and loss of clonogenic survival. These effects of miR-1226 can be attributed, at least in part, to downregulation of MUC1 expression. In this regard, miR-1226 had little if any effect on 293 cells, which are null for MUC1 expression. Nonetheless, these results do not exclude the possibility that the pro-death effects of miR-1226 are mediated by suppression of MUC1 in association with the downregulation of other genes. For example, the BCL2L1 gene encodes the antiapoptotic Bcl-xL protein and has a miR-1226 binding sequence in its 3'UTR (Table I) . Indeed, preliminary results indicate that expression of the miR-1226 mimic decreases BCL2L1 mRNA levels (data not shown). Thus, it is possible that miR-1226-induced downregulation of MUC1 with disruption of redox balance initiates a pro-death response that is further promoted by decreases in the Bcl-xL protein.
Is miR-1226 a tumor suppressor in human cancers? Expression of miR-15 and miR-16 is suppressed in chronic lympho- Table I . Genes with putative miR-1226 binding motifs. MAT2A  NRP1  DLG2  NAT13  CREBBP  CRTAP  SOX11  KCNMA1  FBXO11  TFEC  FOSB  OGT  RPS6KB1  MUC1  IL11RA  MORF4L1  FBXW7  CAMK2G  CCND2  TUSC2  RAB15  PLSCR3  ZMIZ1  OTUB1  ZNF276  MAGF  EIF2C1  BCL2L1  FBXW2  - 
Genes with putative miR-1226 binding motifs (perfect 7 bp complimentarity) in their 3'UTR, as determined by TargetScan and miRanda.
- cytic leukemia cells that have upregulation of Bcl-2 levels (26, 39, 42) . Moreover, miR-29 is decreased in cancer cells with overexpression of Mcl-1 (25, 43) . Our studies in nonmalignant MCF-10A mammary epithelial cells demonstrate that miR-1226 downregulates MUC1 protein levels, indicating that this response is not limited to breast cancer cells. miR-1226 also induced i) increases in ROS, ii) loss of Δaem, and iii) MCF-10A cell death. These results suggest that miR-1226 has a tumor suppressor function and that this role may be abrogated in breast cancer cells. Indeed, the relatively lower levels of miR-1226 in ZR-75-1 cells, compared to that in MCF-10A cells, suggest that overexpression of MUC1 may be due to suppression of miR-1226. Thus, constitutive activation of the MUC1 promoter in breast cancer cells (10, 36) is likely one factor in dictating MUC1 mRNA levels and decreases in miR-1226 may further contribute to the overexpression of MUC1. In addition, in the absence of constitutive MUC1 promoter activation as found in MCF-10A cells (10) , miR-1226 may be functional as a tumor suppressor in preventing aberrant upregulation of MUC1 and a malignant phenotype. If such a model proves correct, then miR-1226 levels will be of importance to the regulation of MUC1 expression and thereby MUC1-induced transformation. Analysis of miRNA expressional databases from human breast cancers will be needed to further define the prognostic significance of miR-1226. However, given the previous lack of functional information regarding miR-1226, to our knowledge none of the publicly available databases have included analyses of miR-1226 expression. The present findings could thus provide the experimental basis for analyzing miR-1226 levels in databases from human breast and other types of cancers that overexpress the MUC1 oncoprotein.
